Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive–compulsive disorder: a double-blind cross-over study

Fux, Mendel; Benjamin, Jonathan; Belmaker, Robert H.

doi:10.1017/s1461145799001546

Cited by 76 publications

(30 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Á The second messenger precursor inositol was superior to placebo in a cross-over trial with 13 patients, but these results have to be regarded as preliminary due to the low sample size in the study (Fux et al 1996). In a DBPC cross-over study with only 10 patients, no significant difference was found between the two treatment phases (Fux et al 1999)(D). Á A DBPC study failed to support the efficacy of St John's wort in OCD (Kobak et al 2005) (E).…”

Section: Other Medicationsmentioning

confidence: 96%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Bandelow

Zohar

Hollander

et al. 2008

The World Journal of Biological Psychiatry

718

410

View full text Add to dashboard Cite

In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo-or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/ SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.

show abstract

Section: Other Medicationsmentioning

confidence: 96%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Bandelow

Zohar

Hollander

et al. 2008

The World Journal of Biological Psychiatry

718

410

View full text Add to dashboard Cite

show abstract

“…Thirteen OCD patients were randomized to either inositol 18 g/day or placebo for 6 weeks, with significantly lower Y-BOCS scores noted in the inositol group. Fux et al (1999) investigated the possible role of inositol as an augmenting agent to SRI treatment in OCD. Ten OCD patients were enrolled in a double-blind, randomized, cross-over study with either inositol 18 g/day or placebo for 6 weeks in addition to their ongoing SRI treatment.…”

Section: Pharmacological Strategiesmentioning

confidence: 99%

Treatment-refractory obsessive-compulsive disorder: Methodological issues, operational definitions and therapeutic lines

Pallanti

Quercioli

2006

Progress in Neuro-Psychopharmacology and Biological Psychiatry

337

190

View full text Add to dashboard Cite

While controlled trials with SRIs have demonstrated a selective efficacy in obsessive-compulsive disorder (OCD), up to 40 -60% of patients do not have a satisfactory outcome. Non-response to treatment in OCD is associated with serious social disability. There are a large number of nonresponsive patients, and they are difficult to cluster due to ambiguities in diagnostic criteria, possibility of subtypes and a high rate of comorbidity. Moreover, the findings of current studies of ''so-called'' non-responsive cases are currently non-generalizable because of the lack of an operational definition of non-response. The result has been that a cumulative body of data on a reasonably homogeneous sample of non-responders has not been developed. The aims of the research in this area are to clarify some of the obstacles in defining stages of response and levels of non-response and, through a comprehensive analysis, to propose a systematic nosology for this rather common condition. Better characterization of which patients respond and do not respond to various treatments will enable more accurate clustering of patients, and help facilitate multisite data collection for future research trials. The authors reviewed also the more recent therapeutic pharmacological and psychological lines for the treatment of refractoriness in OCD. D

show abstract

“…The same group performed another study and examined 10 subjects, diagnosed with OCD. [35] In this crossover study the participants were given 18 g of inositol or placebo for 6 weeks each, in addition to ongoing SSRI treatment. However, no significant differences were found on Y-BOCS, Hamilton Anxiety or Hamilton Depression Rating Scale scores between the two treatment arms.…”

Section: Inositolmentioning

confidence: 99%

Natural remedies for anxiety disorders: potential use and clinical applications

2009

View full text Add to dashboard Cite

show abstract

Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive–compulsive disorder: a double-blind cross-over study

Cited by 76 publications

References 8 publications

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Treatment-refractory obsessive-compulsive disorder: Methodological issues, operational definitions and therapeutic lines

Natural remedies for anxiety disorders: potential use and clinical applications

Contact Info

Product

Resources

About